ClinicalTrials.gg
CompletedNCT00811135Updated Sep 29, 2016Results posted

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer

A Phase 2 interventional study of bevacizumab [Avastin] and capecitabine [Xeloda] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-29.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.

Enrollment
49th of 130
88 · median 58
Started
2008
with 23 others
Phase 2
89 of 131
6 open now
Registered
77th of 131
by date
Lead sponsor
14 of 131
Hoffmann-La Roche

Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 49th largest by enrollment of the 130 interventional ones that give a count, is one of 24 that started in 2008, is one of 89 in phase 2, and was the 77th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies testing bevacizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of Avastin in combination with Herceptin and Xeloda as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancer. Patients will receive 3-weekly treatment cycles of Herceptin (8mg/kg iv on day 1 of first cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles), Xeloda (1000mg/m2 bid po on days 1-14 of each treatment cycle) and Avastin (15mg/kg on day 2 of first treatment cycle,and on day 1 of each subsequent cycle).The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • breast cancer with measurable locally recurrent or lesions;
  • candidate for chemotherapy;
  • -positive disease;
  • PS of \<=2.

Exclusion criteria

Exclusion Criteria:

  • previous anticancer therapy for breast cancer;
  • previous radiotherapy for metastatic breast cancer (except for radiotherapy >=6 months before enrollment);
  • chronic daily treatment with (>=10mg/day), aspirin (>325 mg/day) or clopidogrel (>75mg/day);
  • other primary tumor within last 5 years, except for adequately treated cervical cancer in situ, squamous or basal cell skin cancer;
  • uncontrolled hypertension or significant cardiovascular disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    1

    Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]

Interventions

  • 15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles

  • 1000mg/m2 bid po on days 1-14 of each 3-week cycle

  • 8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)

    Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

Secondary outcomes

  1. Number of Participants With Disease Progression or Death

    Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  2. Progression Free Survival (PFS)

    PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  3. Number of Participants With Overall Survival (OS)

    OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment.

    Time frame: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  4. Overall Survival (OS)

    OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods.

    Time frame: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  5. Number of Participants With Time to Progression (TTP)

    TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  6. Time to Progression (TTP)

    TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions).

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  7. Number of Participants With Response

    Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

  8. Duration of Response (DR)

    DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods.

    Time frame: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)

07

Results

Posted Dec 8, 2015

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab + Bevacizumab + Capecitabine
Started88
Completed0
Not completed88
Withdrew: Adverse event/intercurrent illness8
Withdrew: Death3
Withdrew: Protocol violation2
Withdrew: Violation of selection criteria1
Withdrew: Refused treatment1
Withdrew: Withdrawal by subject3
Withdrew: Administrative/other unspecified11
Withdrew: Ongoing59

Outcome measures

PrimaryPercentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)

Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)
percentage of participantsTrastuzumab + Bevacizumab + Capecitabine
Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR)75.0 (64.6 to 83.6)
SecondaryNumber of Participants With Disease Progression or Death

Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Number · participants
Number of Participants With Disease Progression or Death
participantsTrastuzumab + Bevacizumab + Capecitabine
Number of Participants With Disease Progression or Death70
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsTrastuzumab + Bevacizumab + Capecitabine
Progression Free Survival (PFS)14.2 (10.5 to 14.9)
SecondaryNumber of Participants With Overall Survival (OS)

OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment.

Time frame:
Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Number · participants
Number of Participants With Overall Survival (OS)
participantsTrastuzumab + Bevacizumab + Capecitabine
Number of Participants With Overall Survival (OS)40
SecondaryOverall Survival (OS)

OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods.

Time frame:
Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Median · months
Overall Survival (OS)
monthsTrastuzumab + Bevacizumab + Capecitabine
Overall Survival (OS)31.8 (26.3 to 38.2)
SecondaryNumber of Participants With Time to Progression (TTP)

TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Number · participants
Number of Participants With Time to Progression (TTP)
participantsTrastuzumab + Bevacizumab + Capecitabine
Number of Participants With Time to Progression (TTP)62
SecondaryTime to Progression (TTP)

TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions).

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Median · months
Time to Progression (TTP)
monthsTrastuzumab + Bevacizumab + Capecitabine
Time to Progression (TTP)14.5 (11.0 to 17.0)
SecondaryNumber of Participants With Response

Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Number · participants
Number of Participants With Response
participantsTrastuzumab + Bevacizumab + Capecitabine
Number of Participants With Response66
SecondaryDuration of Response (DR)

DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods.

Time frame:
Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
Reported as:
Median · months
Duration of Response (DR)
monthsTrastuzumab + Bevacizumab + Capecitabine
Duration of Response (DR)12.7 (10.2 to 17.7)

Adverse events

Collected over Up to 28 days after the last study treatment dose (maximum treatment time = approximately 44 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab + Bevacizumab + Capecitabine—20/88 (22.7%)81/88 (92%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTrastuzumab + Bevacizumab + Capecitabine
Cardiac FailureCardiac disorders2/88
DiarrhoeaGastrointestinal disorders2/88
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/88
Intracardiac thrombusCardiac disorders1/88
Abdominal painGastrointestinal disorders1/88
EnteritisGastrointestinal disorders1/88
Intestinal perforationGastrointestinal disorders1/88
Chest painGeneral disorders1/88
DeathGeneral disorders1/88
ErysipelasInfections and infestations1/88
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTrastuzumab + Bevacizumab + Capecitabine
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders65/88
DiarrhoeaGastrointestinal disorders37/88
EpistaxisRespiratory, thoracic and mediastinal disorders35/88
HypertensionVascular disorders34/88
AstheniaGeneral disorders32/88
NauseaGastrointestinal disorders24/88
PyrexiaGeneral disorders18/88
VomitingGastrointestinal disorders15/88
Nail disorderSkin and subcutaneous tissue disorders14/88
HeadacheNervous system disorders14/88

Baseline characteristics

The Intention-To-Treat (ITT) population included all participants enrolled in the study who received at least one dose of any study medication.

Age, Continuous
Age, Continuous(years)Trastuzumab + Bevacizumab + Capecitabine
Mean53.0 ± 10.94
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab + Bevacizumab + Capecitabine
Female87
Male1
08

Study locations

35 sites
  • Herlev, 2730, Denmark
  • Vejle, 7100, Denmark
  • Aix En Provence, 13616, France
  • Beziers, 34500, France
  • Creteil, 94010, France
  • Dechy, 59187, France
  • Lormont, 33310, France
  • Marseille, 13285, France
  • Narbonne, 11780, France
  • Paris, 75475, France
  • Paris, 75571, France
  • Paris, 75651, France
  • Paris, 75970, France
  • Rodez, 12027, France
  • Saint Jean, 31240, France
  • Saint Quentin, 02321, France
  • Toulouse, 31076, France
  • Moscow, 115478, Russian Federation
  • Moscow, 143423, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • Bratislava, 833 10, Slovakia
  • Barakaldo, Vizcaya 48903, Spain
  • Barcelona, 08036, Spain
  • Madrid, 28007, Spain
  • Madrid, 28040, Spain
  • Malaga, 29010, Spain
  • Pontevedra, 36002, Spain
  • Salamanca, 37007, Spain
  • Sevilla, 41013, Spain
  • Valencia, 46010, Spain
  • Valencia, 46026, Spain
  • Eskilstuna, 63188, Sweden
  • Sundsvall, 85186, Sweden
  • Uppsala, 75185, Sweden
  • Vaxjo, 35185, Sweden
09

References and documents

Publications

  • Martin M, Makhson A, Gligorov J, Lichinitser M, Lluch A, Semiglazov V, Scotto N, Mitchell L, Tjulandin S. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. Oncologist. 2012;17(4):469-75. doi: 10.1634/theoncologist.2011-0344. Epub 2012 Mar 30. PubMed 22467666 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, the month primary completion was reached.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2008
First posted
Dec 18, 2008
Start
Dec 2008
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Dec 8, 2015
Last update
Sep 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00811135
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 18, 2008
Start date
Dec 2008
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Dec 8, 2015
Last update
Sep 29, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine · Trastuzumab

Start the discussion